257 related articles for article (PubMed ID: 26078365)
1. Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy.
Thompson A; Cattran DC; Blank M; Nachman PH
J Am Soc Nephrol; 2015 Dec; 26(12):2930-7. PubMed ID: 26078365
[TBL] [Abstract][Full Text] [Related]
2. Membranous Nephropathy: Quantifying Remission Duration on Outcome.
Cattran DC; Kim ED; Reich H; Hladunewich M; Kim SJ;
J Am Soc Nephrol; 2017 Mar; 28(3):995-1003. PubMed ID: 27756808
[TBL] [Abstract][Full Text] [Related]
3. Out of Africa: Complete and partial remissions as a combined outcome in patients with idiopathic membranous glomerulonephritis in Cape Town.
Ameh OI; Swanepoel CR; Aderibigbe A; Kengne AP; Okpechi IG
Nephrology (Carlton); 2016 Dec; 21(12):1010-1016. PubMed ID: 26706191
[TBL] [Abstract][Full Text] [Related]
4. Idiopathic membranous nephropathy: definition and relevance of a partial remission.
Troyanov S; Wall CA; Miller JA; Scholey JW; Cattran DC;
Kidney Int; 2004 Sep; 66(3):1199-205. PubMed ID: 15327418
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
du Buf-Vereijken PW; Branten AJ; Wetzels JF;
Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
[TBL] [Abstract][Full Text] [Related]
6. Association of diabetes with failure to achieve complete remission of idiopathic membranous nephropathy.
Xie H; Li C; Wen Y; Ye W; Cai J; Li H; Li X; Li X
Int Urol Nephrol; 2020 Feb; 52(2):337-342. PubMed ID: 31820359
[TBL] [Abstract][Full Text] [Related]
7. An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.
Troost JP; Trachtman H; Nachman PH; Kretzler M; Spino C; Komers R; Tuller S; Perumal K; Massengill SF; Kamil ES; Oh G; Selewski DT; Gipson P; Gipson DS
Clin J Am Soc Nephrol; 2018 Mar; 13(3):414-421. PubMed ID: 29167190
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting the long-term outcomes of idiopathic membranous nephropathy.
Huh H; Lee H; Lee JP; Kim DK; Oh S; Oh YK; Kim YS; Lim CS
BMC Nephrol; 2017 Mar; 18(1):104. PubMed ID: 28347297
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of persistent disease and relapse in primary membranous nephropathy.
Kanigicherla DA; Short CD; Roberts SA; Hamilton P; Nikam M; Harris S; Brenchley PE; Venning MC
Nephrol Dial Transplant; 2016 Dec; 31(12):2108-2114. PubMed ID: 26769682
[TBL] [Abstract][Full Text] [Related]
10. Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy.
Timmermans SA; Abdul Hamid MA; Cohen Tervaert JW; Damoiseaux JG; van Paassen P;
Am J Nephrol; 2015; 42(1):70-7. PubMed ID: 26344651
[TBL] [Abstract][Full Text] [Related]
11. Clinical Predictors of Response to Prednisone Plus Cyclophosphamide in Patients with Idiopathic Membranous Nephropathy.
Li S; Wang L; Zhang M; Zhou W; Fang W; Wang Q; Qi C; Mou S; Shao X; Ni Z
Nephron; 2017; 135(2):87-96. PubMed ID: 27974710
[TBL] [Abstract][Full Text] [Related]
12. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.
Thompson A; Carroll K; A Inker L; Floege J; Perkovic V; Boyer-Suavet S; W Major R; I Schimpf J; Barratt J; Cattran DC; S Gillespie B; Kausz A; W Mercer A; Reich HN; H Rovin B; West M; Nachman PH
Clin J Am Soc Nephrol; 2019 Mar; 14(3):469-481. PubMed ID: 30635299
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria.
Passerini P; Pasquali S; Cesana B; Zucchelli P; Ponticelli C
Nephrol Dial Transplant; 1989; 4(6):525-9. PubMed ID: 2507973
[TBL] [Abstract][Full Text] [Related]
14. Improving long-term outcomes in idiopathic membranous nephropathy using a distinctive cyclosporine regimen.
Hassan K; Kristal B
Minerva Urol Nefrol; 2016 Jun; 68(3):293-301. PubMed ID: 25645342
[TBL] [Abstract][Full Text] [Related]
15. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
Hofstra JM; Branten AJ; Wirtz JJ; Noordzij TC; du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2010 Jan; 25(1):129-36. PubMed ID: 19666912
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and effects of treatment in older patients with idiopathic membranous nephropathy.
Kim Y; Yoon HE; Chung BH; Choi BS; Park CW; Yang CW; Kim YS; Hong YA; Kim SY; Chang YK; Hwang HS
Korean J Intern Med; 2019 Sep; 34(5):1091-1099. PubMed ID: 31408925
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.
Dussol B; Morange S; Burtey S; Indreies M; Cassuto E; Mourad G; Villar E; Pouteil-Noble C; Karaaslan H; Sichez H; Lasseur C; Delmas Y; Nogier MB; Fathallah M; Loundou A; Mayor V; Berland Y
Am J Kidney Dis; 2008 Oct; 52(4):699-705. PubMed ID: 18585835
[TBL] [Abstract][Full Text] [Related]
18. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome.
Alexopoulos E; Papagianni A; Tsamelashvili M; Leontsini M; Memmos D
Nephrol Dial Transplant; 2006 Nov; 21(11):3127-32. PubMed ID: 16968719
[TBL] [Abstract][Full Text] [Related]
19. Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan.
Yamaguchi M; Ando M; Katsuno T; Tsuboi N; Maruyama S
Ren Fail; 2018 Nov; 40(1):435-441. PubMed ID: 30052488
[TBL] [Abstract][Full Text] [Related]
20. Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus.
Caro J; Gutiérrez-Solís E; Rojas-Rivera J; Agraz I; Ramos N; Rabasco C; Espinosa M; Valera A; Martín M; Frutos MÁ; Perea L; Juárez GF; Ocaña J; Arroyo D; Goicoechea M; Fernández L; Oliet A; Hernández Y; Romera A; Segarra A; Praga M;
Nephrol Dial Transplant; 2015 Mar; 30(3):467-74. PubMed ID: 25274748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
